In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ED in Europe: A Rising Tide?

Executive Summary

Worldwide launches of new PDE5 inhibitors to treat erectile dysfunction are certain to expand the global market for these and other ED therapies. But in Europe, Viagra's brand ubiquity, the prohibition of DTC advertising, and disparate national markets present challenges to firms hoping to dethrone the Pfizer juggernaut.

You may also be interested in...

Sleeping Giant: Europe's Slice of the Global UI Market

The near-dormant global market for urinary incontinence treatments is poised to erupt in the second half of this decade-Novartis' recent acquisition of Pfizer's darifenacin introduces one more global player to the mix. But for existing and novel drug therapies to succeed in the fragmented and particularly underdeveloped European market companies must first recognize the challenges presented by cultural taboo and country-specific regulation.

Bayer Leans on Vardenafil

Dubbed "the new blockbuster" by Bayer AG management, the PDE5 inhibitor vardenafil is by most accounts more potent, faster acting, and less prone to side effects than its pharmaceutical cousin, Pfizer Inc.'s sildenafil (Viagra). But vardenafil's potential-and its role as a potential savior of Bayer's ailing pharmaceuticals division-may be overshadowed by the chinks that this same promise has helped expose in the Bayer armor.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts